Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AstraZeneca, Pozen deal

AZN and POZN changed the milestone and royalty terms of a 2006 deal to co-develop and

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE